Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - A literature review of randomized control trials. World J Gastroenterol 2003; 9(4): 635-640 [PMID: 12679900 DOI: 10.3748/wjg.v9.i4.635]
Corresponding Author of This Article
Hui-Chuan Sun, MD, Associate Professor of Surgery, Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China. sunhc@zshospital.com
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hui-Chuan Sun, Zhao-You Tang, Liver Cancer Institute and Zhong Shan Hospital, Fudan University, Shanghai 200032, China
ORCID number: $[AuthorORCIDs]
Author contributions: All authors contributed equally to the work.
Correspondence to: Hui-Chuan Sun, MD, Associate Professor of Surgery, Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China. sunhc@zshospital.com
Received: September 13, 2002 Revised: October 10, 2002 Accepted: October 17, 2002 Published online: April 15, 2003
Abstract
To review the inhibitory effect of preventive approaches on recurrence after operation in patients with hepatocellular carcinoma (HCC), we summarized all available publications reporting randomized control trial indexed in PubMed. The treatment approaches presented above included pre-operative transcatheter arterial chemoembolization (TACE), post-operative TACE, systemic or locoregional chemotherapy, immunotherapy, Interferons and acyclic retinoic acid. Although no standard treatment has been established, several approaches presented promising results, which were both effective and tolerable in post-operative patients. Pre-operative TACE was not effective on prolonging survivals, while post-operative TACE was shown with both disease-free survival and overall survival benefits in some papers, however, it was also questioned by others. Systemic chemotherapy was generally not effective on prolonging survival but also poorly tolerated for its significant toxicities. Adoptive immunotherapy using LAK cells was proved to be beneficial to patients’ survival in a recent paper. Interferon α and Interferon β can inhibit recurrence in HCC patients with HCV infection background, though the mechanism is not fully understood. Acyclic retinoic acid was shown to decrease multi-centric recurrence after operation, which was reported by only one group. In conclusion, several adjuvant approaches have been studied for their efficacy on recurrence in HCC patients in randomized control trials; however, multi-centric randomized control trial is still needed for further evaluation on their efficacy and systemic or local toxicities; in addition, new adjuvant treatment should be investigated to provide more effective and tolerable methods for the patients with HCC after operation.
Key Words: $[Keywords]
Citation: Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - A literature review of randomized control trials. World J Gastroenterol 2003; 9(4): 635-640
Over the last two decades, the surgical techniques and peri-operative care have been improved, and the operative death (within 30 days after operation) decreased to 2.5%[1], the 5-year overall survival after curative resection of hepatocellular carcinoma (HCC) increased to 25%[1] or 46.7%[2]. However, HCC is far from a curable disease because of high recurrence rate, the 5-year recurrence rate after curative resection was 38%[1] and 61.5%[2], the 5-year disease-free survival was 16%[3] or 38.6%[4] after curative resection of HCC, and the recurrence resulted in most deaths after resection[5].
People have tried a number of approaches to prevent recurrence, however, only a few of them were designed as randomized control trial (RCT), which provide evidence-based results for those treatment modalities. In this paper, the authors summarized those results from randomized control trials, attempting to find a more suitable treatment modality for prevention of recurrence.
IMPORTANT ISSUES RELATED TO EVALUATION OF EFFICACY OF PREVENTION
It is difficult to compare the results among different RCTs because of different study settings and patient collection; therefore, several important issues should be addressed in evaluation of efficacy of prevention of HCC recurrence.
The definition of “curative resection”
The most important issue is the definition of “curative resection” of HCC, because, the definition will greatly affect the recurrence rate. There is no consensus on this definition in the literature. Some authors described it as “complete removal of tumor tissues”[6]; others prefer to “complete removal of tumor tissues plus a clear resection margin ≥ 1 cm on pathological examination”[7]. And some authors used a strict criterion, in which negative findings by angiography followed by Lipiodol-CT and ultrasound one or two months after resection were also included[8]. The 1 year disease-free survival was 43.0% by the first criteria[6], and 59.1% by the second[7], and 69% by the third[8]. The different definitions of curative resection and their results are listed in Table 1.
Table 1 The important issues related to evaluation of efficacy of prevention of recurrence.
The clinicopathological characteristics of patients enrolled in a study also influence the results. For example, tumor size, which was regarded as the age of tumor, affects the recurrence rates and survival after operation, thereafter, has great impact on the results (Table 1).
Origins of recurrence
The origin of recurrence can be divided into two sources, uni-centric and multi-centric origins[9], which could be discriminated by genetic markers, such as HBV integration sites[9,10] or p53 mutation types[11]. Uni-centric origin can also be named as intrahepatic metastatic recurrence or residual tumor, which means metastatic lesion spread from the primary main tumor, and left in the remnant liver. However, multi-centric recurrence is a newly developed lesion in the cirrhotic background. Generally two kinds of recurrences can be roughly divided according to the time of appearance. Twelve months[12] or 3-years[13] were set as a parameter to distinguish them by different authors. A study may be needed to clarify the percentage of uni-centric and multi-centric recurrence by different set point.
Most preventive procedures are targeting the metastatic recurrence, which are used to control the residual tumor cells in the liver. Therefore, 1, 2, 3-year disease-free survival or recurrence rates are used to evaluate the efficacy of preventive procedures targeting metastatic recurrence; however, if a preventive procedure is targeting the multi-centric origin recurrence, 3 or 5-year disease-free survival or recurrence rate should be noticed.
Table 1 showed the overall survival and disease free survival are better when the tumor size decreases, and when a stricter criteria for curative resection was applied. Therefore, when evaluating a preventive treatment targeting residual tumors, it is suggested that a subgroup of patient with more invasive HCC should be enrolled. On the other hand, a subgroup of patient with less invasive HCC or selected by stricter criteria for curative resection should be recruited to investigate a preventive treatment targeting secondary HCC appearance.
LITERATURE REVIEWS OF RANDOMIZED CONTROL TRIALS (RCT) TO PREVENT RECURRENCE OF HCC
Pre-operative or post-operative TACE
TACE has been used to control the growth of HCC for a long time[17]. Pre-operative and post-operative TACE were investigated by RCT to clarify if it reduced the recurrence rate after curative resection of HCC (Table 2).
Table 2 Summary of RCTs to evaluate the efficacy of pre- and post-operative TACE on prevention of recurrence.
Wu et al[16] have studied the effect of pre-operative TACE (preTACE) on resetability and curability in management of huge resectable HCC. Although preTACE induced tumor shrinkage as expected, the shrinkage of tumor didn’t result in an easy operation, on the contrary, the preTACE group had a longer operative time, more blood loss, more extra-hepatic metastasis, higher possibility of invading adjacent organs by tumors and removal of adjacent organs; furthermore, the disease-free survival (DFS) in preTACE group was not statistically different with that in the control group, the overall survival (OS) was even worse than that in control group. The author suggested that preTACE delayed the resection, which may leave tumor more time to develop intra-hepatic or distant metastasis; in addition, preTACE can’t eliminate tumor cells completely, therefore, preTACE for resectable huge HCC was not recommended.
In another study by Yamasaki et al[17], the efficacy of preTACE on small HCC was tested. The results confirmed that preTACE induced necrosis in tumor, but the results demonstrated again that it didn’t improve the DFS, because preTACE was not capable to inhibit the intrahepatic micrometastatic lesions and tumor thrombus in microvessel.
The first RCT study on post-operative TACE (postTACE) was reported by Izumi et al[6] in1994. The authors enrolled 50 patients after curative resection of HCC with blood vessel involvement or intra-hepatic spreadings. The results showed that both DFS rate and DFS time were higher in postTACE group than those in control group. However, 1 and 3-year OS rates were similar in both groups (58.8% vs 63.5%; 30.5% vs 33.9%, P = 0.7647), the median survival time in postTACE was shorter than that in the control group (644.5 ± 129.4 days vs 759.9 ± 137.5 days, P < 0.05). The authors concluded that postTACE may postpone but not eliminate the recurrence (60.9% vs 81.5%, P = 0.106).
In another RCT reported by Lau et al[7], the authors used 131I-Lipiodol instead of conventional Lipiodol. The result showed that postTACE improved DFS and OS, decreased recurrence without major side-effects. This is the only one RCT reporting a positive result for postTACE treatment. The authors suggested more effective agents should be used in postTACE.
However, in Lai et al[8]’s study of postTACE, although the preventive treatment protocol was more aggressive than Izumi’s study, the result was even worse. The recurrence rate and extrahepatic metastasis rate were higher in postTACE group (recurrence rate: 23/30 vs 17/36, P = 0.01) extrahepatic metastasis rate: 11/30 vs 5/36, P = 0.03); 3-year DFS in postTACE group was lower than that in the control group (18% vs 48%, P = 0.04). The OS in postTACE group was worse than that in the control group, especially in the first two years, but the difference was not statistically significant. Therefore, the authors concluded postTACE is harmful to patients after curative resection of HCC.
The reason of why conflicting results came from different RCTs is the selection of patients. Lai et al’s group of patients was selected by a highly rigorous standard; the rationale of preventive treatment was not solid enough to protect this group of patient with interventional treatment like postTACE. However, in Izumi and Lau’s studies, the authors selected a group of patients with more possibility of recurrence (invasive cancer or large cancer), so the results turned out to be effective.
In summary, preTACE is not helpful in terms of decreasing recurrence after resection of resectable HCC. PostTACE is only beneficial to the patients with invasive HCC, but not effective or even harmful to the patients after a “real” curative resection.
Systemic or locoregional chemotherapy
Systemic chemotherapy is generally not effective in most cases with HCC[18], only a few papers showed a favorable results of systemic chemotherapy[19]. Here is a summary of RCTs studying post-operative systemic and locoregional chemotherapy (Table 3).
Table 3 Summary of locoregional or systemic chemotherapy for prevention of recurrence.
Yamamoto et al[20] studied systemic chemotherapy using HCFU 200 mg bid as a adjuvant treatment for the patients after curative resection of HCC. The result showed that systemic chemotherapy was effective in a subgroup of patients with mild cirrhosis and good liver function, but not effective in a subgroup of patients with severe cirrhosis and poor liver function. The authors discussed that systemic chemotherapy inhibited the growth of micro-metastatic lesions existing before operation or multi-centric carcinogenesis after operation, but jeopardized liver function as well, which resulted a negative effect on both OS and DFS, especially in patients with poor liver function reserve.
Kohno et al[21] studied the result of an aggressive treatment combining systemic and one course of transcatheter arterial chemotherapy (TAC). There was no obvious side-effect of this treatment. However, the results showed this combination treatment did not improve the 3 and 5-year OS and DFS compared with the control group with UFT treatment alone, and another control group without any specific treatment.
Ono et al[22]’s treatment protocol was even more aggressive with combining systemic and multiple courses of TAC, however, the result was still negative. Furthermore, very aggressive protocol was intolerable to most enrolled patients, and too many cases withdrew from this study.
Ueno et al[23]’s study showed multiple courses of TAC improved DFS after curative resection of HCC. The flaw of this study is too small sample size.
A recent meta-analysis also showed that systemic chemotherapy was not effective or even harmful as an adjuvant treatment in patients after resection of HCC[24]. Another meta-analysis showed that TAE (transcatheter arterial embolization) improved OS after resection of HCC compared with TAC, and no evidence showing TACE was more effective than TAE[25], which implied a very limited benefit of locoregional chemotherapy introduced by TACE overtopping TAE alone.
From the above data, it is suggested that systemic or locoregional chemotherapy didn’t inhibit the recurrence, and the tolerance was another important factor influencing the results.
Post-operative adoptive immunotherapy
Post-operative active or adoptive immunotherapy became a very attractive cancer treatment modality in early 1990s because of a series of successful animal experiments[26]; however, it turned out to be not so effective as expected in a number of clinical trials[27-29]. At the same time, several clinical trials have been set up to test the effect of adoptive immunotherapy on recurrence in patients with HCC in early 1990s. The followings are a summary of these RCTs (Table 4).
Table 4 A summary of RCT results of adoptive immunotherapy to prevent recurrence.
Une et al[30]’s study compared the effect of locoregional chemotherapy with locoregional chemotherapy plus systemic immunotherapy on recurrence after curative resection of HCC. The results showed that locoregional chemotherapy plus systemic immunotherapy decreased recurrence rate. However, Kawata et al[31], reported from the same institution and used almost identical treatment settings, demonstrated immunochemotherapy didn’t present any survival benefit to the patients, although in a subgroup of patients with negative surgical margin (≥ 1 cm), the immunochemotherapy group had a better disease-free survival rate than the chemotherapy group. The reason of the difference might come from the different observation time.
Lygidakis et al[32] employed a protocol combining pre-operative and post-operative locoregional chemotherapy with systemic immunotherapy to prevent post-operative recurrence in HCC patients. The results showed this protocol decreased recurrence.
In Takayama’s study, which had a more than 5-year observation time, presented a clear survival benefit from adoptive immunotherapy in terms of DFS but not OS. To explain the reason of that, the authors discussed that adoptive immunotherapy may eliminate the micrometastatic lesion in the remnant liver, but can’t prevent multicentric recurrence; the second reason was, during a longer time of observation, the treatment choice for recurrence was not totally dependent on doctors’ presetting, therefore different treatment modalities may affect the long term results[1].
In general, the immunotherapy may inhibit recurrence in patients after resection of HCC, especially in the first several years after operation, with a good tolerance. However, it needs more randomized control trial to confirm, and more powerful agents need to be discovered.
Post-operative Interfereon (IFN) treatment
The rationale of post-operative IFN treatment came from the several findings in HCV related HCC. First, a lower incidence of HCC was observed in many studies when IFN was used to clear HCV viremia[33]; second, recurrence after curative resection of HCC developed from multicentric origin, which was closely related to the HCC viremia status[14]. Third, IFN had anti-cancer effect on the early stage tumors, like micrometastatic lesions[34]. The following is the summary of post-operative IFN treatment (Table 5).
Ikeda et al[35]’s results showed that, although the recurrence curve increased similarly in both groups in the first two years, but it remained the same in treatment group after that, which suggested that the effect of IFNβ on prevention of recurrence was not through direct inhibition of tumor cells per se, but depended on the clearance of HCV viremia, implying the mechanism of IFNα is through inhibition of multicentric recurrence. However, in Kubo et al[14,36]’s study, the decrease of recurrence rate was associated with neither clearance of HCV nor normalization of serum ALT level, the actual reason was unknown, but the authors suggested that it might depend on direct antitumor effects or inhibition of carcinogenesis by HCV. Therefore, the mechanism of IFN’s effect on recurrence remains to be investigated further. Recently, our data suggested anti-angiogenesis instead of the anti-proliferation property of IFNα involving in antitumor effect in animal models, and it may act through regulation of VEGF expression. A randomized control trial in HBV related HCC patients after curative resection was also conducted to test the effect of IFNα on recurrence in the authors’ institution, the interim results showed that long-term IFNα treatment improved disease-free survival of patients through direct antitumor effect, which was not associated with serum conversion of HBeAg.
Acyclic retinoid acid
Retinoid acid is a inducer of differentiation. All-trans retinoic acid has been successfully used to treat a subtype of leukemia. Muto et al[37,38] reported a serial results in patients with HCV-related HCC treated by post-operative acyclic retinoic acid (ARA), and showed long term ARA treatment improvement in OS and DFS. A further study revealed the mechanism of ARA treatment was through inhibition of second primary liver cancer by deletion of a latent clonal hepatoma cells[39] (Table 6).
A number of preventive treatment protocols to inhibiting recurrence after curative resection of HCC have been evaluated by RCT. Although no standard treatment has been proven to be effective to all patients, several approaches presented promising results, which were both effective and tolerable in post-operative patients. Generally systemic and locoregional chemotherapy or combined with embolization was not as effective as expected, meanwhile the side-effects, such as downstaging of liver function was noticed in this treatment; however, biological treatment approaches showed a better outcome, but need more evidence before being accepted widely.
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet. 2000;356:802-807.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 630][Cited by in F6Publishing: 634][Article Influence: 26.4][Reference Citation Analysis (0)]
Tang ZY, Yu YQ, Zhou XD, Ma ZC, Wu ZQ. Progress and prospects in hepatocellular carcinoma surgery.Ann Chir. 1998;52:558-563.
[PubMed] [DOI][Cited in This Article: ]
Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma.World J Gastroenterol. 2002;8:385-392.
[PubMed] [DOI][Cited in This Article: ]
Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G, Tsurumaru M. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma.Cancer. 1993;71:19-25.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 7][Reference Citation Analysis (0)]
Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA.Hepatology. 1999;29:1446-1452.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 58][Cited by in F6Publishing: 64][Article Influence: 2.6][Reference Citation Analysis (0)]
Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.Cancer. 2000;89:500-507.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 13][Reference Citation Analysis (0)]
Sugimoto R, Okuda K, Tanaka M, Aoyagi S, Kojiro M. Metachronous multicentric occurrence of hepatocellular carcinoma after surgical treatment - clinicopathological comparison with recurrence due to metastasis.Oncol Rep. 1999;6:1303-1308.
[PubMed] [DOI][Cited in This Article: ]
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.Ann Intern Med. 2001;134:963-967.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 199][Cited by in F6Publishing: 215][Article Influence: 9.3][Reference Citation Analysis (0)]
Tang ZY, Yu YQ, Zhou XD. An important approach to prolong-ing survival further after radical resection of AFP positive hepa-tocellular carcinoma.J Exp Clin Cancer Res. 1984;4:359-366.
[PubMed] [DOI][Cited in This Article: ]
Yamasaki S, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K, Kakumoto Y, Saitsu H, Yamada R, Oosaki Y. A prospective random-ized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma.Jpn J Cancer Res. 1996;87:206-211.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 120][Cited by in F6Publishing: 123][Article Influence: 4.4][Reference Citation Analysis (0)]
Kohno H, Nagasue N, Hayashi T, Yamanoi A, Uchida M, Ono T, Yukaya H, Kimura N, Nakamura T. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC).Hepatogastroenterology. 1996;43:1405-1409.
[PubMed] [DOI][Cited in This Article: ]
Ono T, Nagasue N, Kohno H, Hayashi T, Uchida M, Yukaya H, Yamanoi A. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.Semin Oncol. 1997;24:S6-18-S6-S6-18-25.
[PubMed] [DOI][Cited in This Article: ]
Ueno S, Tanabe G, Yoshida A, Yoshidome S, Takao S, Aikou T. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis.Cancer. 1999;86:248-254.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 4][Reference Citation Analysis (0)]
Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carci-noma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.Can-cer. 2001;91:2378-2385.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 9][Reference Citation Analysis (0)]
Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.J Clin Oncol. 1993;11:1441-1447.
[PubMed] [DOI][Cited in This Article: ]
Hanna MG, Hoover HC, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise.Vaccine. 2001;19:2576-2582.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 95][Cited by in F6Publishing: 98][Article Influence: 4.3][Reference Citation Analysis (0)]
Une Y, Kawata A, Uchino J. [Adopted immunochemotherapy using IL-2 and spleen LAK cell--randomized study].Nihon Geka Gakkai Zasshi. 1991;92:1330-1333.
[PubMed] [DOI][Cited in This Article: ]
Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.Anticancer Res. 1995;15:543-550.
[PubMed] [DOI][Cited in This Article: ]
Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.Hepatology. 2000;32:228-232.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 259][Cited by in F6Publishing: 266][Article Influence: 11.1][Reference Citation Analysis (0)]
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.Br J Surg. 2002;89:418-422.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 120][Cited by in F6Publishing: 135][Article Influence: 6.1][Reference Citation Analysis (0)]
Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.N Engl J Med. 1996;334:1561-1567.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 509][Cited by in F6Publishing: 465][Article Influence: 16.6][Reference Citation Analysis (0)]
Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma.Clin Cancer Res. 1997;3:727-731.
[PubMed] [DOI][Cited in This Article: ]
